The new patent is directed to a topical composition for alleviating bruising caused by a cosmetic procedure—INhance Post-Injection Serum with TriHex Technology.

Alastin Skincare, Inc. received a fourth U.S. Patent from the United States Patent and Trademark Office.

The new patent, which incorporates TriHex Technology, is directed to a topical composition for alleviating bruising caused by a cosmetic procedure—INhance Post-Injection Serum with TriHex Technology.   

"I love the new INhance Post-Injection Serum with TriHex Technology which has improved patient satisfaction with injectable procedures as a result of noticeable reductions in black and blue color of the bruise and post-procedure swelling,” says Dr. Shino Bay Aguilara of Shino Bay Cosmetic Dermatology and Laser Institute, in a news release. “The added antiaging benefits of TriHex Technology in supporting the skin's ability to create new collagen and elastin make the addition of INhance Post-Injection Serum a must-have in any aesthetic practice." 

"We are immensely proud of the scientific investment we have made in validating TriHex Technology performance in our product formulations which is confirmed by its numerous patents.  INhance Post-Injection Serum combines the antiaging benefits of patented TriHex Technology and our new ChromaFADE Technology to deliver state of the art post-procedure recovery and skin-enhancing benefits," adds Dr. Alan Widgerow, MBBCh (MD); MMed (MHS); FCS; FACS and Chief Medical Officer at Alastin.